Edward Peres is an Oncology physician affiliated with Henry Ford Health System. OpenAlex indexes 90 publications with 1,383 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2799 W Grand Blvd
Detroit, MI 482022608
Telephone
800-653-6568Registry record last updated 23 Jan 2014.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Incyte CorporationProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
16%Proton pump inhibitor9.4%Omeprazole70%Pantoprazole Sodium30%Part D<11 patientsOsmotically acting laxatives4.4%Magnesium Sulfate100%Part D<11 patients+ 1 more class in this area
Dermatology
15.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.7%Acyclovir100%Part D≥35 patientsCancer & immunology
14.5%Calcineurin inhibitor5.5%Tacrolimus100%Part D≥11 patientsKinase inhibitor5.2%Jakafi100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tocilizumab Prophylaxis Following Idecabtagene Vicleucel in the Outpatient Setting in Patients with Relapsed or Refractory Multiple Myeloma
Biology of Blood and Marrow Transplantation
2026 - Budesonide for Engraftment Fever Prophylaxis: A Single Center Randomized Study Interim Analysis
Biology of Blood and Marrow Transplantation
2025 - Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial
International Journal of Infectious Diseases
2024 - A Phase I/II Study of GDA-201, Cryopreserved Nicotinamide-Enhanced Allogeneic Natural Killer Cells, in Patients with Relapsed/Refractory B-Cell Lymphoma
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Kalkanis, MD
Henry Ford Health System
Shirish Gadgeel, MD
Henry Ford Health System
Mani Menon, MD
Henry Ford Health System
Marcus Zervos, MD
Henry Ford Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”